Exhibit 99.1
          Court Rules in Favor of ARIAD and Co-Plaintiffs in
            Lilly NF-(kappa)B Patent Infringement Lawsuit:
                  Patent Found Valid and Enforceable

       U.S. Patent & Trademark Office Issues Final Office Action

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 9, 2007--ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) and its co-plaintiffs today
announced that Judge Rya W. Zobel of the United States District Court
for the District of Massachusetts has found in favor of the plaintiffs
in their lawsuit against Eli Lilly and Company ("Lilly") alleging
infringement of the plaintiffs' pioneering U.S patent covering methods
of treating human disease by regulating NF-(kappa)B cell-signaling
activity. The Judge's opinion found that the patent is valid and
enforceable and that judgment may be entered for the plaintiffs in
accordance with the verdict of the jury and the Court's findings of
fact and conclusions of law.

    In May 2006, the jury ruled unanimously in favor of the plaintiffs
in finding that the claims of the NF-(kappa)B patent asserted in the
lawsuit are valid and infringed with respect to Lilly's osteoporosis
drug, Evista(R), and Lilly's septic shock drug, Xigris(R). The jury
awarded damages to the plaintiffs in the amount of approximately $65.2
million, based on the jury's determination of a reasonable royalty
rate of 2.3% to be paid by Lilly to the plaintiffs based on U.S. sales
of Evista and Xigris from filing of the lawsuit on June 25, 2002
through February 28, 2006. The jury awarded further damages on an
ongoing basis, in amounts to be determined, equal to 2.3% of U.S.
sales of Evista and Xigris through the year 2019, when the patent
expires.

    The co-plaintiffs are Massachusetts Institute of Technology, The
Whitehead Institute for Biomedical Research, and The President and
Fellows of Harvard College.

    "We are extremely pleased with the Court's decision which upholds
the validity and enforceability of our pioneering NF-(kappa)B patent
and believe this is a significant step forward for ARIAD and our
co-plaintiffs," said Harvey J. Berger, M.D., chairman and chief
executive officer of ARIAD. "While Lilly has the right to challenge
the verdict, we are confident that the verdict will be upheld by the
U.S. Court of Appeals for the Federal Circuit."

    ARIAD also announced today that the U.S. Patent and Trademark
Office issued a final Office action in its reexamination of the
NF-(kappa)B patent (U.S. Patent No. 6,410,516) and rejected the
patentability of certain claims of the patent, including those claims
being asserted in the Lilly lawsuit and a separate lawsuit against
Amgen, Inc. and Wyeth. ARIAD plans to respond to this Office action
promptly and, if necessary, appeal the decision through all
appropriate means of review within the Patent Office and the courts.
The NF-(kappa)B patent remains valid and enforceable through the
appeals process. The Company estimates that the entire appeals process
relating to the reexamination may take approximately two years, or
longer.

    About ARIAD

    ARIAD is engaged in the discovery and development of breakthrough
medicines to treat cancer by regulating cell signaling with small
molecules. The Company is developing a comprehensive approach to
patients with cancer that addresses the greatest medical need -
aggressive and advanced-stage cancers for which current treatments are
inadequate. Medinol Ltd. also is developing stents and other medical
devices that deliver ARIAD's lead cancer product candidate to prevent
reblockage at sites of vascular injury following stent-assisted
angioplasty. ARIAD has an exclusive license to pioneering technology
and patents related to certain NF-(kappa)B treatment methods, and the
discovery and development of drugs to regulate NF-(kappa)B
cell-signaling activity, which may be useful in treating certain
diseases. Additional information about ARIAD can be found on the web
at http://www.ariad.com.

    This press release contains "forward-looking statements,"
including statements related to our NF-(kappa)B patent litigation and
reexamination. Forward-looking statements are based on management's
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events, timing
and performance to differ materially from those expressed or implied
by such statements. These risks and uncertainties include, but are not
limited to, the costs associated with our research, development,
manufacturing and other activities, the conduct and results of
pre-clinical and clinical studies of our product candidates,
difficulties or delays in obtaining regulatory approvals to market
products resulting from our development efforts, our reliance on
partners and other key parties for the successful development,
manufacturing and commercialization of products, the adequacy of our
capital resources and the availability of additional funding, patent
protection and third-party intellectual property claims relating to
our and any partner's product candidates, the timing, scope, cost and
outcome of legal and patent office proceedings concerning our
NF-(kappa)B patent portfolio, the potential acquisition of or other
strategic transaction regarding the minority stockholders' interests
in our 80%-owned subsidiary, ARIAD Gene Therapeutics, Inc., future
capital needs, key employees, markets, economic conditions, prices,
reimbursement rates, competition and other factors detailed in the
Company's public filings with the U.S. Securities and Exchange
Commission. The information contained in this document is believed to
be current as of the date of original issue. The Company does not
intend to update any of the forward-looking statements after the date
of this document to conform these statements to actual results or to
changes in the Company's expectations, except as required by law.


    CONTACT: For ARIAD Pharmaceuticals, Inc.
             Ed Fitzgerald, 617-621-2345
             or
             Pure Communications
             Sheryl Seapy, 949-608-0841